Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Shares Outstanding (Weighted Average) (2016 - 2025)

Lexaria Bioscience's Shares Outstanding (Weighted Average) history spans 10 years, with the latest figure at $13.9 million for Q2 2024.

  • For Q2 2024, Shares Outstanding (Weighted Average) rose 115.11% year-over-year to $13.9 million; the TTM value through May 2024 reached $13.9 million, up 115.11%, while the annual FY2023 figure was $6.6 million, 12.38% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q2 2024 was $13.9 million at Lexaria Bioscience, up from $10.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $13.9 million in Q2 2024 and bottomed at $2.7 million in Q1 2020.
  • The 5-year median for Shares Outstanding (Weighted Average) is $5.9 million (2022), against an average of $6.0 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) crashed 96.5% in 2020 before it soared 115.11% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $3.0 million in 2020, then surged by 90.8% to $5.7 million in 2021, then grew by 3.92% to $6.0 million in 2022, then skyrocketed by 52.1% to $9.1 million in 2023, then skyrocketed by 53.07% to $13.9 million in 2024.
  • Per Business Quant, the three most recent readings for LEXX's Shares Outstanding (Weighted Average) are $13.9 million (Q2 2024), $10.8 million (Q1 2024), and $9.1 million (Q4 2023).